45
131
2
↑45
↓131
—2
Evidence suggests Melatonin maydecreaseCancer incidence.
127 studies (178 claims)
Moderate consensus
Typical effective dose 26.5 (14.75–38.25) mgacross 2 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| Disruption of the circadian nocturnal melatonin signal | Increases - promotes | growth, metabolism, and signaling of human breast cancer | Human | animal and human models | Not specified | Melatonin: A Potential Therapeutic Option for Breast Cancer.cited 38× |
| Melatonin | Decreases - has significant inhibitory effects | numerous cancers, especially breast cancer | Human | — | Not specified | Melatonin: A Potential Therapeutic Option for Breast Cancer.cited 38× |
| circadian disruption of melatonin synthesis | Increases - linked to increased breast cancer risk | breast cancer risk | Human | — | Not specified | Melatonin and breast cancer: Evidences from preclinical and human studies.cited 80× |
| melatonin | Decreases - inverse correlation | risk of breast cancer | Human | — | Not specified | Melatonin and breast cancer: Evidences from preclinical and human studies.cited 80× |
| melatonin | Decreases - has a significant anti-tumor activities | various cancer types | Human | — | Not specified | Melatonin and breast cancer: Evidences from preclinical and human studies.cited 80× |
| melatonin alone or in combined administration | No effect - seems to be appropriate drug for the treatment | early stages of breast cancer | Human | — | Not specified | Melatonin and breast cancer: Evidences from preclinical and human studies.cited 80× |
| endogenously-produced melatonin | No effect - impacts | metabolic phenotype of cancer cells | HumanMolecular | solid tumors, particularly breast cancer | Not specified | Part-time cancers and role of melatonin in determining their metabolic phenotype.cited 17× |
| melatonin | Increases - would improve | cancer treatment outcomes | HumanMolecular | — | Not specified | Part-time cancers and role of melatonin in determining their metabolic phenotype.cited 17× |
| exogenously-administered melatonin | No effect - impacts | metabolic phenotype of cancer cells | HumanMolecular | solid tumors, particularly breast cancer | Not specified | Part-time cancers and role of melatonin in determining their metabolic phenotype.cited 17× |
| Melatonin | Decreases - exerts | anti-cancer effects | Molecular | — | Not specified | Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved.cited 13× |
| Melatonin | Decreases - inhibits | hypoxia-induced cancer cell survival, invasion, migration, and metabolism | Molecular | — | Not specified | Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved.cited 13× |
| Co-administration of melatonin in combination with other therapeutic medications | Increases - might increase | effectiveness of anti-cancer drugs | Molecular | — | Not specified | Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved.cited 13× |
| melatonin | Increases - exhibits | anti-cancer properties | Molecular | — | Not specified. | Multifaceted roles of melatonin in oncology: an insight into its therapeutic potential in cancer management. |
| melatonin | Increases - control of | apoptosis in lung cancer | Human | — | — | Potential role of melatonin in prevention and treatment of lung cancer.cited 5× |
| melatonin | No effect - control of | autophagy in lung cancer | Human | — | — | Potential role of melatonin in prevention and treatment of lung cancer.cited 5× |
| melatonin | Decreases - control of | cell proliferation in lung cancer | Human | — | — | Potential role of melatonin in prevention and treatment of lung cancer.cited 5× |
| melatonin | No effect - control of | immunomodulation in lung cancer | Human | — | — | Potential role of melatonin in prevention and treatment of lung cancer.cited 5× |
| melatonin | Decreases - shows anticancer effects | lung cancer | Human | — | — | Potential role of melatonin in prevention and treatment of lung cancer.cited 5× |
| melatonin | Decreases - exerts pleiotropic anticancer effects | a variety of cancer types | HumanMolecular | — | Not specified | Melatonin as a potential anticarcinogen for non-small-cell lung cancer.cited 78× |
| melatonin | Decreases - may provide a defense against | a variety of cancer types | Human | — | Not specified | Melatonin as a treatment for gastrointestinal cancer: a review.cited 77× |
| melatonin | Increases - promotion of | cancer immunity | Human | — | Not specified | Melatonin as a treatment for gastrointestinal cancer: a review.cited 77× |
| melatonin | Decreases - ability to inhibit | gastrointestinal cancer | Human | — | Not specified | Melatonin as a treatment for gastrointestinal cancer: a review.cited 77× |
| melatonin | Decreases - growth-inhibitory effects | gastrointestinal cancer | Human | — | Not specified | Melatonin as a treatment for gastrointestinal cancer: a review.cited 77× |
| melatonin | No effect - exhibits various functions in controlling the behavior of cancer cells | behavior of cancer cells | Human | — | — | Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy.cited 36× |
| melatonin | Affects - changes in | biosynthesis of estrogen in breast cancer cells | HumanMolecular | breast cancer cells | Not specified | Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization.cited 84× |
| melatonin | Decreases - has the potential to prevent metastatic and invasive nature | breast cancer | Human | — | Not specified. | The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor.cited 28× |
| melatonin | Decreases - anti-metastatic effect | breast cancer | Human | — | Not specified. | The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor.cited 28× |
| melatonin | Increases - induction | cancer cells sensitivity to the chemotherapy agents | Human | — | Not specified. | The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor.cited 28× |
| melatonin | Decreases - protective effect | cancer invasion and metastasis | Human | — | Not specified. | The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor.cited 28× |
| melatonin | No effect - poorly documented to conclude on a positive effect | breast cancer | HumanMolecular | — | Not specified | Protective role of melatonin in breast cancer: what we can learn from women with blindness.cited 2× |
| melatonin | Decreases - protective and therapeutic role | breast cancer | HumanMolecular | blind women | Not specified | Protective role of melatonin in breast cancer: what we can learn from women with blindness.cited 2× |
| melatonin | Decreases - significant incidence decreases | breast cancer risk | HumanMolecular | totally blind women | Not specified | Protective role of melatonin in breast cancer: what we can learn from women with blindness.cited 2× |
| melatonin levels | No effect - absence of correlation | breast cancer occurrence | HumanMolecular | premenopausal women | Not specified | Protective role of melatonin in breast cancer: what we can learn from women with blindness.cited 2× |
| melatonin levels | Decreases - significantly decreased risk | breast cancer occurrence | HumanMolecular | postmenopausal women | Not specified | Protective role of melatonin in breast cancer: what we can learn from women with blindness.cited 2× |
| melatonin | No effect - will become one of the most common therapeutic drugs | breast cancer | Human | — | — | Molecular and cellular mechanisms of melatonin in breast cancer.cited 9× |
| melatonin | No effect - is an appropriate candidate for treatment | cancer | Human | — | — | Molecular and cellular mechanisms of melatonin in breast cancer.cited 9× |
| melatonin | Decreases - inhibits the development of | breast cancer | Molecular | — | Not mentioned | Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms.cited 14× |
| melatonin | Decreases - may suppress | cancer development | Molecular | in vitro and animal models | Not mentioned | Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms.cited 14× |
| melatonin | Decreases - has antitumor properties on | different cancer types | Molecular | — | Not mentioned | Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms.cited 14× |
| melatonin | Decreases - inhibits | breast cancer cell growth | Human | — | Not specified | Melatonin, an inhibitory agent in breast cancer.cited 68× |
| melatonin | Decreases - capable of inhibiting | cancer cell invasion | Human | — | Not specified | Melatonin, an inhibitory agent in breast cancer.cited 68× |
| melatonin | Decreases - reverse correlation | development of mammary cancer | Human | — | Not specified | Melatonin, an inhibitory agent in breast cancer.cited 68× |
| melatonin | Decreases - is toxic to | breast cancer cell survival | Molecular | breast cancer cells | Not specified | Breast cancer: Occluded role of mitochondria N-acetylserotonin/melatonin ratio in co-ordinating pathophysiology.cited 20× |
| Melatonin | Decreases - display anti-proliferative effects on | breast cancer growth and proliferation | Human | — | Not specified | Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients.cited 11× |
| Melatonin levels | No effect - correlate with | clinical and psychological symptoms of breast cancer | Human | — | Not specified | Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients.cited 11× |
| melatonin | No effect - important role | breast cancer prevention and adjuvant therapy | HumanMolecular | — | Not specified | The Role of Oxidative Stress Modulators in Breast Cancer.cited 73× |
| Melatonin | Decreases - is a promising hormone for preventing cancer | cancer | Human | — | Not specified | Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment.cited 63× |
| Melatonin | Increases - improving cancer treatment | cancer treatment | Human | — | Not specified | Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment.cited 63× |
| melatonin | Decreases - has substantial anticancer properties | cancer | Human | clinical oncology | Not specified | The emergence of melatonin in oncology: Focus on colorectal cancer.cited 48× |
| melatonin | Decreases - shows wide range anticancer activities | cancer | Human | — | Not specified | Melatonin: A new inhibitor agent for cervical cancer treatment.cited 54× |
| melatonin | Decreases - inhibitory effects | cervical cancer | Human | — | Not specified | Melatonin: A new inhibitor agent for cervical cancer treatment.cited 54× |
| melatonin | Decreases - anticervical cancer effects | cervical cancer | Human | — | Not specified | Melatonin: A new inhibitor agent for cervical cancer treatment.cited 54× |
| Melatonin | Decreases - has anticancer properties | cancer | Molecular | — | Not specified | Melatonin and its ubiquitous anticancer effects. |
| Melatonin | Decreases - has anticancer properties | cancer | Molecular | — | Not specified | Melatonin and its ubiquitous anticancer effects. |
| Melatonin | Decreases - anticancer effect | cancer | Molecular | various cancer cells | Not specified | Melatonin and its ubiquitous anticancer effects. |
| Melatonin | Decreases - anticancer effect | cancer | Molecular | various cancer cells | Not specified | Melatonin and its ubiquitous anticancer effects. |
| Melatonin | Decreases - has oncostatic effects | cancer growth | Molecular | various oncological cells | Not specified | Melatonin and its ubiquitous anticancer effects. |
| Melatonin | Decreases - has oncostatic effects | cancer growth | Molecular | various oncological cells | Not specified | Melatonin and its ubiquitous anticancer effects. |
| melatonin | Decreases - having anticancer potentials | cancer | Human | — | Not available | Melatonin and neuroblastoma: a novel therapeutic approach.cited 11× |
| melatonin | Decreases - has anti-cancer characteristics | cancer | Molecular | — | Not specified | Molecular targets for the management of gastrointestinal cancer using melatonin, a natural endogenous body hormone.cited 6× |
| melatonin | Increases - apoptotic induction | cancer cell apoptosis | Molecular | — | Not specified | Molecular targets for the management of gastrointestinal cancer using melatonin, a natural endogenous body hormone.cited 6× |
| melatonin | Decreases - antiproliferative | cancer cell proliferation | Molecular | — | Not specified | Molecular targets for the management of gastrointestinal cancer using melatonin, a natural endogenous body hormone.cited 6× |
| melatonin | Decreases - cytotoxic | cancer cells | Molecular | — | Not specified | Molecular targets for the management of gastrointestinal cancer using melatonin, a natural endogenous body hormone.cited 6× |
| melatonin | Decreases - antimetastatic | cancer metastasis | Molecular | — | Not specified | Molecular targets for the management of gastrointestinal cancer using melatonin, a natural endogenous body hormone.cited 6× |
| therapeutic melatonin administration | No effect - possibility for | cancer therapy | Molecular | — | Not specified | Molecular targets for the management of gastrointestinal cancer using melatonin, a natural endogenous body hormone.cited 6× |
| melatonin | Decreases - anticancer effects | cancer | Human | — | — | Use of Melatonin in Cancer Treatment: Where Are We?cited 47× |
| melatonin | Decreases - exerts its anticancer effect through modification of its receptors | cancer | Human | — | — | Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin. |
| melatonin | Decreases - exerts its anticancer effect through modification of its receptors | cancer | Human | — | — | Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin. |
| melatonin | Decreases - inhibition of cancer cell proliferation | cancer cell proliferation | Human | — | — | Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin. |
| melatonin | Decreases - inhibition of cancer cell proliferation | cancer cell proliferation | Human | — | — | Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin. |
| melatonin | Decreases - has potential anti-cancer properties | cancer | Human | — | Not specified | Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations.cited 7× |
| melatonin | Decreases - halt cancer cell proliferation | cancer cell proliferation | Human | osteosarcoma | Not specified | Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations.cited 7× |
| Melatonin | Decreases - emerging as one of the most effective ... oncostatic molecule | cancer | HumanAnimal | human | — | Photoimmunomodulation and melatonin. |
| melatonin | Decreases - inhibit | cancer | Molecular | — | Not specified. | Melatonin modulates tumor metabolism and mitigates metastasis.cited 10× |
| melatonin | Decreases - reverse | cancer chemoresistance | Molecular | — | Not specified. | Melatonin modulates tumor metabolism and mitigates metastasis.cited 10× |
| melatonin | Increases - function synergistically with | conventional cancer-inhibiting drugs | Molecular | — | Not specified. | Melatonin modulates tumor metabolism and mitigates metastasis.cited 10× |
| melatonin | Decreases - inhibitory effects on | numerous cancer types | Molecular | — | Not specified. | Melatonin modulates tumor metabolism and mitigates metastasis.cited 10× |
| melatonin | Decreases - shows a wide range of anticancer activities | cancer | HumanMolecular | — | Not specified | Molecular and Cellular Mechanisms of Melatonin in Osteosarcoma.cited 35× |
| melatonin | Decreases - fortify the anti-cancer effects | cancer | HumanMolecular | osteosarcoma models | Not specified | Molecular and Cellular Mechanisms of Melatonin in Osteosarcoma.cited 35× |
| melatonin | Decreases - may be of use in the prevention and treatment | cancer | Human | human, animal and cellular studies | Not specified | Mechanisms Underlying Tumor Suppressive Properties of Melatonin.cited 47× |
| melatonin | Decreases - has oncostatic properties | cancer | Human | human, animal and cellular studies | Not specified | Mechanisms Underlying Tumor Suppressive Properties of Melatonin.cited 47× |
| melatonin | Decreases - mitigates pathogenesis | cancer | Human | — | Not specified | Mechanisms Underlying Tumor Suppressive Properties of Melatonin.cited 47× |
| melatonin | Decreases - retard the progression | cancer | Human | — | Not specified | Mechanisms Underlying Tumor Suppressive Properties of Melatonin.cited 47× |
| melatonin | Increases - beneficial outcomes | cancer treatment | Human | — | Not specified | Mechanisms Underlying Tumor Suppressive Properties of Melatonin.cited 47× |
| melatonin | Decreases - mitigates | cancer at the initiation, progression and metastasis phases | Human | — | Not specified | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.cited 310× |
| melatonin | Decreases - restrains | cancer development and growth | Human | — | Not specified | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.cited 310× |
| melatonin | Increases - increasing their efficacy | efficacy of anti-cancer drugs | Human | — | Not specified | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.cited 310× |
| melatonin | Decreases - limiting the entrance of cancer cells into the vascular system | entrance of cancer cells into the vascular system | Human | — | Not specified | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.cited 310× |
| melatonin | Decreases - reducing the toxic consequences of anti-cancer drugs | toxic consequences of anti-cancer drugs | Human | — | Not specified | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.cited 310× |
| melatonin | Increases - appears to affect | cancer cell death | HumanMolecular | — | Not available. | Molecular Interactions of Autophagy with the Immune System and Cancer.cited 25× |
| melatonin | Decreases - inhibitory effects on | cancer cell growth | Human | — | Not specified | Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases.cited 4× |
| melatonin (MLT) | Decreases - decreasing | cancer cell growth | Human | — | Not specified | Melatonin and cisplatin co-treatment against cancer: A mechanistic review of their synergistic effects and melatonin's protective actions.cited 2× |
| Melatonin | Decreases - has significant inhibitory effects on | cancer cell proliferation | Human | — | Not specified | Melatonin as a Promising Agent for Cancer Treatment: Insights into its Effects on the Wnt/beta-catenin Signaling Pathway.cited 3× |
| Melatonin | Decreases - is a significant inhibitor of | cancer initiation, progression, and metastasis | Human | — | Not specified | Melatonin as a Promising Agent for Cancer Treatment: Insights into its Effects on the Wnt/beta-catenin Signaling Pathway.cited 3× |
| melatonin | Decreases - may inhibit | cancer cell proliferation | HumanMolecular | cancer cells | Not specified | Melatonin for gastric cancer treatment: where do we stand? |
| Melatonin | Decreases - works against | cancer cell proliferation, motility, and invasiveness | HumanMolecular | — | Not specified | Human hepatocellular carcinoma: Protection by melatonin.cited 56× |
| melatonin | Increases - triggering pro-apoptotic signals | cancer cells | Molecular | null | Nanomolar range (exact dosage not specified) | Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review.cited 142× |
| melatonin | Increases - activates the intrinsic and/or the extrinsic apoptotic pathway | cancer cells | Molecular | null | Nanomolar range (exact dosage not specified) | Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review.cited 142× |
| melatonin | Increases - shares a selective pro-apoptotic action | cancer cells | HumanMolecular | cancer cells | Not specified | Melatonin as a proteasome inhibitor. Is there any clinical evidence?cited 53× |
| melatonin | Decreases - potent inhibitory effects | cancer cells | HumanMolecular | — | Not specified | Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer.cited 38× |
| melatonin | Decreases - exerts its effects | cancer pathogenesis | HumanMolecular | — | Not specified | Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer.cited 38× |
| melatonin | Decreases - combat | formation of cancer cells | HumanMolecular | — | Not specified | Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer.cited 38× |
| melatonin | Increases - may be an effective apoptosis inducer | cancer cells | Molecular | — | Not specified | Melatonin and pancreatic cancer: Current knowledge and future perspectives.cited 38× |
| melatonin supplementation | No effect - is an appropriate therapeutic approach | pancreatic cancer | Molecular | in vivo and in vitro studies | Not specified | Melatonin and pancreatic cancer: Current knowledge and future perspectives.cited 38× |
| melatonin | Increases - selectively radiosensitise | cancer cells | Human | — | Not specified | Ionizing Radiation as a Source of Oxidative Stress-The Protective Role of Melatonin and Vitamin D.cited 83× |
| melatonin | Increases - has pro-oxidant effects | cancer cells | HumanMolecular | cancer cells | Not specified | Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy.cited 21× |
| melatonin | Decreases - has pro-oxidant as well as anti-proliferative, anti-angiogenic and immunomodulatory properties | cancer cells | HumanMolecular | many cancer types including hormone-dependent cancers | Not specified | Melatonin as a promising agent to treat ovarian cancer: molecular mechanisms.cited 53× |
| melatonin | Increases - modulates the signaling pathways involved in cancer cell apoptosis, survival, inflammation, proliferation and metabolic processes | signaling pathways involved in cancer cell apoptosis, survival, inflammation, proliferation and metabolic processes | HumanMolecular | OC cells | Not specified | Melatonin as a promising agent to treat ovarian cancer: molecular mechanisms.cited 53× |
| Melatonin | Increases - aids sensitizing | cancer cells to therapy | Molecular | some cancer cells | Not specified. | Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review.cited 94× |
| melatonin | No effect - management | cancer correlates | HumanMolecular | — | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | No effect - influence | cancer growth | HumanMolecular | — | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | No effect - influence | cancer initiation | HumanMolecular | — | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | No effect - effects | cancer patients' life quality | HumanMolecular | cancer patients | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | Decreases - prevention | cancer tumorigenesis | HumanMolecular | in vivo and in vitro | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | No effect - correlation | melatonin levels and cancer risk | HumanMolecular | — | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | Decreases - involved in the inhibition | cancer development | Human | — | Not mentioned | The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis.cited 22× |
| LAN-evoked disruption of the nocturnal increase in melatonin synthesis | Decreases - counteracts | preventive action on human cancer development and progression | Human | human | Not mentioned | The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis.cited 22× |
| melatonin | Decreases - potential to suppress | cancer initiation | Molecular | — | Not specified | Therapeutic targets of cancer drugs: Modulation by melatonin.cited 23× |
| melatonin | Decreases - potential to suppress | cancer progression | Molecular | — | Not specified | Therapeutic targets of cancer drugs: Modulation by melatonin.cited 23× |
| melatonin | Decreases - has anti-carcinogenic features | cancer progression | Human | — | Not specified | Melatonin is a potential inhibitor of ovarian cancer: molecular aspects.cited 26× |
| melatonin | No effect - significant beneficial roles | various types of cancers including ovarian cancer | Human | — | Not specified | Melatonin is a potential inhibitor of ovarian cancer: molecular aspects.cited 26× |
| melatonin | No effect - therapeutic benefits | cancer protection | Human | — | Not specified | Physiological and pharmacological perspectives of melatonin.cited 30× |
| impaired melatonin secretion | Increases - promotes | cancer progression | Human | — | Not specified | Physiological and pharmacological perspectives of melatonin.cited 30× |
| melatonin | Decreases - viable candidates for the treatment | Cancer-related Cachexia (CAC) | HumanMolecular | cancer patients | Not mentioned | Cancer-associated Cachexia, Reactive Oxygen Species and Nutrition Therapy.cited 14× |
| melatonin | Increases - reinforcing the therapeutic effects | cancer therapies | HumanMolecular | — | Not specified | Melatonin for the prevention and treatment of cancer. |
| melatonin | Increases - reinforcing the therapeutic effects | cancer therapies | HumanMolecular | — | Not specified | Melatonin for the prevention and treatment of cancer. |
| melatonin | No effect - plays a role in cancer therapy | cancer therapy | HumanMolecular | — | Not specified | Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.cited 12× |
| melatonin | Increases - apoptotic effects | renal cancer cells | HumanMolecular | renal cancer cells | Not specified | Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.cited 12× |
| melatonin | Decreases - anti-angiogenic effects | renal cancer cells | HumanMolecular | renal cancer cells | Not specified | Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.cited 12× |
| melatonin | No effect - suggests potential | cancer therapy | Human | — | Not specified. | A review of the potential use of melatonin in cancer treatment: Data analysis from Clinicaltrials.gov.cited 1× |
| melatonin | Increases - improve | cancer therapy | Molecular | — | Not specified | Regulation of Cell Death Mechanisms by Melatonin: Implications in Cancer Therapy.cited 8× |
| melatonin (N-acetyl-5-metoxy-tryptamine) (MLT) | No effect - antioxidant activity | cancer treatment potential | Molecular | — | Not provided. | A Review on Melatonin's Effects in Cancer: Potential Mechanisms. |
| melatonin (N-acetyl-5-metoxy-tryptamine) (MLT) | No effect - antioxidant activity | cancer treatment potential | Molecular | — | Not provided. | A Review on Melatonin's Effects in Cancer: Potential Mechanisms. |
| melatonin (N-acetyl-5-metoxy-tryptamine) (MLT) | Decreases - limiting or reversing | changes occurring during cancer development and growth | Molecular | — | Not provided. | A Review on Melatonin's Effects in Cancer: Potential Mechanisms. |
| melatonin (N-acetyl-5-metoxy-tryptamine) (MLT) | Decreases - limiting or reversing | changes occurring during cancer development and growth | Molecular | — | Not provided. | A Review on Melatonin's Effects in Cancer: Potential Mechanisms. |
| melatonin | Increases - may also enhance the efficacy of | cancer treatments such as immuno- and chemotherapy | Human | — | — | The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.cited 14× |
| melatonin | Decreases - has been observed to suppress | growth of cancer cells | Human | in vitro and in vivo models | — | The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.cited 14× |
| melatonin | Decreases - impairs melatonin's ability to reduce both cell proliferation and clonogenic potential of cancer cells | cell proliferation and clonogenic potential of cancer cells | Molecular | cancer cells | — | Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. |
| melatonin | Increases - favors in activating | colon cancer immunity | Human | — | Not specified | Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin Antioncogenic Action.cited 20× |
| melatonin | Decreases - functions as an inhibitor of | cytosolic glycolysis in cancer cells | HumanMolecular | cancer cells | Not mentioned | Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis.cited 49× |
| melatonin | Decreases - halts | the proliferative activity of cancer cells | HumanMolecular | cancer cells | Not mentioned | Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis.cited 49× |
| melatonin | No effect - levels have been observed to be altered | different cancers, such as breast cancer, colorectal cancer endometrial cancer, and hematopoetical cancers | Human | — | Not specified. | Melatonin: A promising agent targeting leukemia.cited 17× |
| melatonin | Decreases - could inhibit | different types of cancer | Molecular | in vitro and in vivo | Not specified | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.cited 117× |
| melatonin | Decreases - decreasing | drug resistance in cancer therapy | Molecular | — | Not specified | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.cited 117× |
| melatonin | Increases - potentiates | gemcitabine's cancer-suppressing effects | Animal | pancreatic cancer xenograft model in rats | 50 mg/kg, intraperitoneally, three times per week | Melatonin augments anti-tumor activity and alleviates nephrotoxicity of gemcitabine in a pancreatic cancer xenograft model targeting P62/Keap1 pathway. |
| Melatonin | Decreases - inhibits | growth and invasive capacity of colon cancer cells | HumanMolecular | in vitro | — | Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer. |
| Melatonin | Decreases - inhibits | human breast cancer cells stimulated with estrogen | HumanMolecular | human MCF-7 cell line | Dose-dependent (specific amounts not provided). | Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review.cited 27× |
| melatonin | Decreases - suppressing | human prostate cancer | Human | human prostate cancer | Not specified | The inhibitory effect of melatonin on human prostate cancer.cited 23× |
| melatonin | Decreases - preventing, diagnosing and treating | human prostate cancer | Human | human prostate cancer | Not specified | The inhibitory effect of melatonin on human prostate cancer.cited 23× |
| melatonin | No effect - played a role in | liver cancer | Human | — | Not available | Circadian Rhythm and Melatonin in Liver Carcinogenesis: Updates on Current Findings.cited 3× |
| melatonin | Decreases - potential clinical application for the treatment of | liver cancer | Human | — | Not available | Circadian Rhythm and Melatonin in Liver Carcinogenesis: Updates on Current Findings.cited 3× |
| melatonin (MLT) | No effect - antiproliferative and immunomodulatory effects | neoplasms including colorectal cancer (CRC) | Human | humans and other mammals | — | The profile of melatonin receptors gene expression and genes associated with their activity in colorectal cancer: a preliminary report. |
| melatonin | Decreases - exhibit therapeutic activities against | neurodegenerative, psychiatric disorders and cancer | Human | — | Not specified | Significance of Melatonin in the Regulation of Circadian Rhythms and Disease Management.cited 15× |
| melatonin | No effect - targets | nutrients and oxygen supply to cancer cells | Molecular | — | Not specified | Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence.cited 80× |
| melatonin | Decreases - role in oral cancer prevention and control | oral cancer | Human | — | Not available | Preventive measures in oral cancer: An overview.cited 114× |
| melatonin | Decreases - may also impede the progression of | oral cancer | Human | — | Not specified | Therapeutic potential of melatonin in oral medicine and periodontology.cited 30× |
| melatonin | Decreases - inhibits | oral cancer progression | Human | — | Not specified | Melatonin and oral diseases: possible therapeutic roles based on cellular mechanisms.cited 2× |
| melatonin | Decreases - is effective in the adjunctive therapy of | osteoporosis, cataract, sepsis, neurodegenerative diseases, hypertension, and even cancer | Human | — | Not specified | Melatonin in experimental seizures and epilepsy.cited 73× |
| melatonin | Decreases - may have properties protective against | ototoxic drugs such as amikacin, gentamicin, or cancer therapeutic agents that are dose dependent | HumanMolecular | — | 1 to 3 mg daily (modest doses mentioned). | Does melatonin have therapeutic use in tinnitus?cited 3× |
| melatonin | No effect - has antiproliferative, antiangiogenic, apoptotic, and immunomodulatory properties | ovarian cancer | Human | — | — | The Relationship Between Melatonin 1-2 Receptor Expression in Patients With Epithelial Ovarian Cancer and Survival. |
| melatonin | Decreases - may have beneficial effects in | periodontal disease, herpes and oral cancer | Human | — | Not specified | A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. |
| melatonin | Decreases - may have beneficial effects in | periodontal disease, herpes and oral cancer | Human | — | Not specified | A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. |
| melatonin | Decreases - suppress | prion-mediated, non-Mendelian, heritable, but often reversible epigenetic adaptations that facilitate cancer heterogeneity, stemness, metastasis, and drug resistance | HumanMolecular | — | Not mentioned | Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance.cited 13× |
| Melatonin | Decreases - has been shown to inhibit | proliferation of estrogen receptor α (ERα)-positive human breast cancer cells | AnimalMolecular | in vitro | — | In vitro and in vivo antitumor activity of melatonin receptor agonists. |
| melatonin (MLT) | Decreases - significant | risk of breast cancer | Human | — | Not specified | Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action.cited 55× |
| melatonin | Decreases - has been proposed to have protective effects | skin cancer | Human | — | Not specified | Melatonin's protective effect against UV radiation: a systematic review of clinical and experimental studies.cited 20× |
| melatonin | No effect - promises to be useful in | skin cancer prevention | Human | — | Not specified | Melatonin: A Cutaneous Perspective on its Production, Metabolism, and Functions.cited 203× |
| Melatonin | Decreases - blocks | the recurrence of prostate cancer | HumanMolecular | — | Not specified | The Potential Oncostatic Effects of Melatonin against Prostate Cancer. |
| Melatonin | Decreases - blocks | the recurrence of prostate cancer | HumanMolecular | — | Not specified | The Potential Oncostatic Effects of Melatonin against Prostate Cancer. |
| melatonin | Decreases - has significant apoptotic, angiogenic, oncostatic, and antiproliferative effects | various cancer cells | Human | — | Not specified | New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence.cited 22× |
| pineal melatonin | No effect - epigenetic modifications mediated by | cancer prevalence | Human | — | Not mentioned | Artificial light at night: melatonin as a mediator between the environment and epigenome.cited 71× |
| Melatonin treatment | Decreases - inhibited | cancer cell invasion | AnimalMolecular | Huh7 and HepG2 HCC cells | Not specified | Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma. |
| Melatonin treatment | Decreases - inhibited | cancer cell migration | AnimalMolecular | Huh7 and HepG2 HCC cells | Not specified | Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma. |
| Melatonin treatment | Decreases - inhibited | cancer cell proliferation | AnimalMolecular | Huh7 and HepG2 HCC cells | Not specified | Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma. |
| endogenous and exogeneous melatonin | No effect - has impact on | prevention of cancer progression | Human | — | Not specified | Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseases.cited 41× |
| melatonin receptor genetic polymorphisms | Increases - implicated in | cancer | HumanMolecular | — | Not specified | Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease. |
| melatonin receptor genetic polymorphisms | Increases - implicated in | cancer | HumanMolecular | — | Not specified | Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease. |
| melatonin and mesenchymal stem cells | No effect - effects of | functional integrity for liver cancer treatment | Molecular | — | Not mentioned | Melatonin and Mesenchymal Stem Cells as a Key for Functional Integrity for Liver Cancer Treatment.cited 13× |
| Melatonin supplementation | Decreases - decrease in | symptoms induced by cancer and cancer treatment | Human | older patients | Not mentioned | Quality of life for older patients with cancer: a review of the evidence supporting melatonin use.cited 7× |
| melatonin suppression | Increases - has been associated with | cancer risk | Human | — | Not specified | Alcohol and melatonin.cited 14× |
| the combinational melatonin therapy | Decreases - reduced | Cancer cell viability | Human | — | Not specified | Adjuvant chemotherapy with melatonin for targeting human cancers: A review.cited 49× |
| Melatonin signaling via melatonin receptor type 1 (MT1) | Decreases - inhibits | prostate cancer cell proliferation | AnimalMolecular | in vitro cell cultures | — | Disruption of Melatonin Signaling Leads to Lipids Accumulation in the Liver of Melatonin Proficient Mice. |
| melatonin receptors | No effect - have broad therapeutic implications | chronobiology, immunomodulation, endocrine regulation, reproductive functions and cancer development | Human | — | Not specified | A molecular and chemical perspective in defining melatonin receptor subtype selectivity. |
| melatonin receptors | No effect - have broad therapeutic implications | chronobiology, immunomodulation, endocrine regulation, reproductive functions and cancer development | Human | — | Not specified | A molecular and chemical perspective in defining melatonin receptor subtype selectivity. |
| low level of circulatory melatonin concentration | Increases - influences the development of | many cancers, including breast cancer | Molecular | — | — | Melatonin: A Potential Antineoplastic Agent in Breast Cancer. |
| low level of circulatory melatonin concentration | Increases - influences the development of | many cancers, including breast cancer | Molecular | — | — | Melatonin: A Potential Antineoplastic Agent in Breast Cancer. |
| vitamin D and melatonin supplementation | Decreases - highlights the importance | side‑effects from cancer treatments | Human | — | Not specified | Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy (Review).cited 5× |
| melatonin and polyphenols | No effect - suggested to play an important role | prevention and treatment of cancer | Human | — | Not specified | Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin.cited 30× |